Research Peptide Quality Checklist for CoA Review

For institutional buyers, a research peptide quality checklist is less a shopping list than a document-control routine. When a tirzepatide CoA arrives in a procurement inbox, the question is not simply whether the file looks professional, but whether purity, identity, and batch match can be traced back to a specific production lot through verifiable laboratory records. This guide sets out a structured checklist for reviewing a tirzepatide CoA, written for research procurement teams, laboratory managers, and QA reviewers who need to document their supplier evaluation before placing an order.

Start with document control, not the purity number

Most reviewers open a CoA and scan straight to the purity figure. That is the wrong order. A purity result is only meaningful if the document itself is controlled: issued by a named laboratory, tied to a specific lot, dated, and traceable to raw analytical data. Before reading any result, confirm the following:

• Document identifier: a unique CoA number or report ID that can be quoted in your purchase file.
• Issue date and revision status: a clear date of analysis and, where applicable, a revision history.
• Laboratory identity: the testing organization named, with a contact route and, where claimed, accreditation scope.
• Method references: the analytical method cited for each test, not just the result.
• Signature or authorization block: an identifiable reviewer or approving analyst.

A CoA that omits these elements is not automatically invalid, but it shifts the burden of verification onto the buyer. For a fuller walkthrough of the document structure, see the Helix CoA guide, which sets out the fields a complete certificate should carry.

Purity: read the method before the percentage

HPLC purity is the most quoted figure on a peptide CoA and the most frequently misread. A stated purity of, for example, 98% means little without knowing the chromatographic conditions, the detection wavelength, the integration method, and whether the value is area percent or a corrected assay. Your checklist should capture:

Chromatographic conditions

• Column type and dimensions, mobile phase composition, gradient, flow rate, and detection wavelength.
• Whether a representative chromatogram is attached, with retention time and peak integration shown.
• Whether related substances or impurity peaks are reported individually or only as a total.

Purity versus assay

HPLC area percent and assay by an independent technique answer different questions. Area percent describes the proportion of UV-absorbing material in the main peak; assay quantifies the actual content of the target peptide against a reference standard. A CoA that reports only one of these should state clearly which, and your checklist should record the distinction so that downstream reviewers do not conflate them.

Water content and counterion

Peptide salts carry water and counterions that affect how a purity figure should be interpreted. Where reported, note Karl Fischer water content, residual solvents, or trifluoroacetate content alongside the purity result.

Identity: confirm the molecule, not just the peak

Identity testing is where a research peptide quality checklist earns its keep. A single sharp HPLC peak confirms that one principal species is present; it does not confirm that the species is tirzepatide. Mass spectrometry, typically ESI-MS or MALDI-TOF, should report an observed mass against the theoretical mass of the target sequence, with the mass error stated. Amino acid analysis or peptide mapping may supplement this for higher-assurance programs.

Record on your checklist:

• Theoretical versus observed molecular mass, and the accepted mass tolerance.
• The ionization method and instrument class used.
• Whether the identity result is linked to the same lot as the purity result.
• Sequence confirmation, where provided, and the method used.

If identity and purity results appear to come from different analytical runs, confirm that both refer to the same lot. This is a common point of ambiguity in supplier documentation and one worth resolving in writing before procurement approval.

Batch match: the link between document and vial

Batch match is the control that ties the certificate to the material you will actually receive. A CoA for lot A does not describe lot B, however similar the two documents look. Your checklist should require that the lot or batch number on the CoA matches the lot number on the product label, the outer packaging, and the packing list, character for character.

Where a supplier provides a batch-specific CoA per order, confirm the sequence: the lot number is assigned at manufacture, the sample is drawn from that lot, the analytical results are recorded against it, and the certificate is issued before dispatch. For a worked example of how batch matching is reviewed in practice, the Helix tirzepatide CoA walkthrough sets out the fields to cross-reference between certificate and shipment.

Traceability questions to put to the supplier

• Is the CoA issued per lot, and can a lot-specific certificate be provided for the exact batch shipped?
• How long are raw analytical data and retention samples held?
• Can a second, independent laboratory result be supplied on request?
• What is the procedure if a received lot fails your incoming review?

Stability, handling, and storage documentation

Analytical quality at release does not describe a peptide after shipping and storage. Add to your checklist any available stability data, recommended storage conditions, and shipping configuration, including whether cold-chain packaging and temperature indicators are used. For lyophilized research peptides, note the stated reconstitution and storage guidance in the supplier's technical documentation, and record whether that guidance is consistent with your laboratory's own handling procedures.

Putting the checklist to work in procurement

A checklist is only useful if it produces a decision record. For each supplier evaluation, retain the CoA, the lot number, the shipment documentation, and a signed-off review noting any gaps and how they were resolved. Where a document is incomplete, request the missing element in writing rather than inferring it. Institutional buyers should also confirm that the supplier's quality documentation is available before order placement, not only after a purchase order is raised.

Helix Peptide supplies research peptides under GMP-aligned manufacturing and documentation practices, with lot-specific certificates available for procurement review. Buyers who need to confirm documentation scope, testing arrangements, or batch-specific records before ordering can talk to the QA team directly.

Conclusion: a repeatable research peptide quality checklist

The value of a research peptide quality checklist lies in consistency. Applied to every tirzepatide CoA your organization receives, it converts a stack of supplier documents into a comparable record of purity, identity, and batch match, and it makes gaps visible before they become procurement problems. Keep the checklist short enough to be used on every order, specific enough to capture method and lot detail, and linked to a retained file so that each decision can be defended later. For buyers sourcing GLP-1 research peptides at institutional scale, that discipline is the difference between a certificate on file and a verifiable quality record.

Ready to review documentation for your next order? Request a quote and lot-specific CoA from Helix Peptide via the contact page.